New drug combo shows promise against rare brain cancer

NCT ID NCT06115824

Completed Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at 136 people with newly-diagnosed primary central nervous system lymphoma (a rare brain cancer). Researchers compared standard chemo alone versus chemo plus the targeted drug orelabrutinib. The goal was to see if the combination improved tumor shrinkage and delayed cancer growth. Results are being analyzed to determine if adding orelabrutinib is more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib (a targeted cancer drug taken as a pill)
What this could lead to: If successful, adding orelabrutinib to standard chemo could improve tumor shrinkage and delay cancer progression in people with newly-diagnosed primary CNS lymphoma.
What could go wrong: This is a small, single-center retrospective study, not a randomized trial. Results may not apply broadly, and orelabrutinib may cause side effects like infections or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Department of Hematology, Huashan Hospital, Fudan University

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.